Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

A research paper by scientists at the Capital Medical University evaluated sex differences in stroke recurrence among ...

One month of dual antithrombotic therapy followed by direct oral anticoagulation alone may be as safe vs. 1 year of dual ...

Medical device company XCath announced on Nov. 12 the successful treatment of three patients with brain aneurysms using its ...

Spryte Medical, a pioneer in intravascular neuro imaging, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the ...

A recent study published in the Journal of the American Medical Association found that the risk of a first intracranial ...

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in ...

A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain.

A bakery stand in an Eau Claire neighborhood aims to help one little boy reach his full potential. In the Eastside Hill ...

Radiation-induced brain injury (RIBI) is a serious and often delayed complication of cranial radiotherapy, which remains a cornerstone in the treatment of brain tumors such as gliomas, metastases, and ...

Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0, a next-generation approach to A ...